IDL Diagnostics AB (publ) IDLDX.ST · SEK

Its shares trade on Nasdaq Stockholm under the ticker IDLDX.ST. It has been listed since 25 May 2011. In the fiscal year to 31 December 2025, it reported revenue of SEK 53.1m and a net loss of SEK 12.2m. At that date it held total assets of SEK 176.9m and shareholders' equity of SEK 148.2m.

AroCell AB is a in vitro diagnostics company, which engages in the monitoring of hematological malignancies, breast cancer, and other solid tumors. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-25. The firm's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Claes PostChairman of the Board, since 2017SEK 250,000
• Mr. Anders HultmanChief Executive OfficerSEK 1.7m
• Mr. Lars JakobssonChief Financial Officer
• Mr. Gustav StoneChief Operating Officer
• Ms. Anne-christine NilssonChief Scientific Officer
• Mr. Sofia ForsbergChief Quality Officer
• Mr. Peter LowendahlSenior Director Regulatory Affairs
• Mr. Gunnar SteineckChief Medical Officer, since 2017SEK 53,000
• Ms. Marie TorstenssonChief Sales Officer, Laboratory
• Mr. Gunnar WahlbergChief Sales Officer, Rapid
• Mr. Per-anders AbrahamssonDirector
• Ms. Karin Eriksson-VidblomDirectorSEK 150,000

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.